Gili Hart
Director/Board Member at ENLIVEX THERAPEUTICS LTD.
Net worth: 4 591 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Avri Havron | M | 76 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | 19 years |
| Yosef Cohen | M | 49 | 14 years | |
| Pini Mandel | M | 46 | 14 years | |
| Roger Pomerantz | M | 67 | 4 years | |
| Shai Novik | M | 58 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 23 years |
| Elan Penn | M | 72 | 6 years | |
| Herzel Naftali Laks | M | 48 | 2 years | |
| Alisa Lask | F | 53 | 3 years | |
| Joseph Zarzewsky | M | 63 | 5 years | |
| Andrew Singer | M | 53 | 1 years | |
| Hugh Evans | M | 58 | 3 years | |
| Amichai Helman | M | 45 | 3 years | |
| Oren Hershkovitz | M | 47 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 8 years |
| Dror Mevorach | M | 68 | 15 years | |
| Keren Primor Cohen | F | 48 | 3 years | |
| Einat Galamidi | M | - | 2 years | |
| Sigal Arad | M | - | - | |
| Elana Gazal | M | 49 | 2 years | |
| Hadas Dreiher-Horowitz | F | 47 | 3 years | |
| Avri Katzir | M | 49 | 4 years | |
| Or Stokelman | M | 38 | 4 years | |
| Veronique Amor-Baroukh | M | - | - | |
| Iris Tavor | F | - | - | |
| Yeshai Kav | M | 45 | 6 years | |
| Stanley Fiel | M | - |
SpliSense Ltd.
 SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | - |
| Shachar Shlosberger | F | 47 | 8 years | |
| Oren Elmaliah | M | 40 | 7 years | |
| Steven Rubin | M | 63 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 11 years |
| Shay Lang | M | - | 1 years | |
| Gal Yaffe | M | 48 | 2 years | |
| Daniel Spira | M | 69 | 3 years | |
| Gidon Zairi | M | - |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | 4 years |
| Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 years |
| Adam Logal | M | 46 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 10 years |
| Brian Schwartz | M | 52 | 4 years | |
| Avia Ben Hamo | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter L. Coker | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Phillip Frost | M | 87 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 years |
| Adam Stern | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Udi Eyal Fima | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Bernhard Kirschbaum | M | 65 | - | |
| David Tsur | M | 73 | 2 years | |
| David Hochman | M | 48 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 years |
| Michel Moise Habib | M | 57 | - | |
| Scott Burell | M | 59 | 2 years | |
| Marian Gorecki | M | 83 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 9 years |
| Jane Hsaio | M | 77 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 years |
| Shomrat Shurtz | F | 57 | 3 years | |
| Michal Roytman | M | 39 | - | |
| Hyun Gyu Lee | M | - | - | |
| Shmuel Hess | M | 51 | - | |
| Sangwoo Lee | M | 52 | 6 years | |
| Baruch Halpert | M | 57 | - | |
| Revital Mandil–Levin | M | 49 | 1 years | |
| Jonathan Rigby | M | 56 | - | |
| Eugene Bauer | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Robert F. Mauer | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 1 years |
| Joel Kanter | M | 67 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Wolfgang Ruttenstorfer | M | 73 | 1 years | |
| Alastair Clemow | M | 72 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 2 years |
| Marina Gofman Feler | F | 35 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 61 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gili Hart
- Personal Network
